Is Summit Therapeutics Stock a Buy?

Its alliance with a successful foreign biotech could be decisive for the stock. Summit Therapeutics' (SMMT -8.44%) shares are up by more than 1,060% in the last 12 months, thanks to the market's exuberant reaction to the latest sets of clinical trial data produced by the company and its main collaborator. Now the question is whether Summit can continue wowing investors as its candidates approach their shot at commercialization. But you might look at its pipeline and conclude that the biotech is a one-trick ...